6 not yet recruiting, 5 recruiting, 4 active not recruiting, 4 completed. 10 Phase 2, 10 Phase 3, 3 Not applicable, 2 Phase 1, 2 Phase 4.
Follow Newly Diagnosed Multiple Myeloma: new trials by email Literature Review of Newly Diagnosed Multiple Myeloma trials Research Report on Newly Diagnosed Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Isatuximab, Iberdomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 88 | 2026-09-03 | 2026-09-03 |
| ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide - Multiple Myeloma, Newly Diagnosed Multiple Myeloma | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 160 | 2026-08-01 | 2026-06-23 |
| Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Daratumumab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma, Multiple Myeloma | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2026-07-01 | 2026-06-09 | |
| A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen Sotoclax, Carfilzomib, Lenalidomide - Newly Diagnosed Multiple Myeloma, T(11;14) | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 20 | 2026-07-01 | 2026-07-17 |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT AZD0120, Daratumumab, Dexamethasone - Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | AstraZeneca | 750 | 2026-06-26 | 2026-08-14 |
| A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma HLX15-IV, Darzalex - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 386 | 2025-04-01 | 2025-03-26 |
| A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma a combination treatment of Linperlisib and the VRD regimen - Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Fuling Zhou | 42 | 2025-02-01 | 2025-01-29 |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) Belantamab mafodotin, Lenalidomide, Dexamethasone - Multiple Myeloma, Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | GlaxoSmithKline | 520 | 2024-12-16 | 2026-04-22 |
| Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients Carfilzomib - Newly Diagnosed Multiple Myeloma | Recruiting | The First Affiliated Hospital of Soochow University | 50 | 2024-09-10 | 2024-11-12 | |
| Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation Cyclophosphamide, Lenalidomide - Newly Diagnosed Multiple Myeloma | Phase 2 / Phase 3 | Unknown | Jinling Hospital, China | 80 | 2023-04-16 | 2024-03-21 |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients Isatuximab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 2 / Phase 3 | Recruiting | University Hopsital Schleswig Holstein Campus Lübeck | 100 | 2023-02-03 | 2024-12-11 |
| NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Bortezomib, Isatuximab, Iberdomide - Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | PETHEMA Foundation | 480 | 2022-11-10 | 2026-06-25 |
| Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens - Newly Diagnosed Multiple Myeloma | Unknown | The First Affiliated Hospital of Soochow University | 120 | 2022-10-01 | 2022-09-30 | |
| Biomarkers in Multiple Myeloma Blood samples - Hematological Patients, Newly Diagnosed Multiple Myeloma | Not applicable | Active not recruiting | Centre Hospitalier Universitaire de Saint Etienne | 70 | 2022-05-20 | 2026-10-13 |
| A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM Daratumumab - Newly Diagnosed Multiple Myeloma | Not applicable | Unknown | The First Affiliated Hospital of Soochow University | 76 | 2021-12-01 | 2021-10-21 |
| Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM Isatuximab-Irfc 20 MG/ML [Sarclisa], Lenalidomide, Dexamethasone Oral - Newly Diagnosed Multiple Myeloma | Phase 2 | Active not recruiting | Arbeitsgemeinschaft medikamentoese Tumortherapie | 198 | 2021-10-20 | 2025-04-10 |
| Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Bortezomib 3.5 MG - Newly Diagnosed Multiple Myeloma | Phase 4 | Withdrawn | Al-Rasheed University College | 2020-03-01 | 2023-04-28 | |
| Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Daratumumab, Bortezomib, Lenalidomide - Newly Diagnosed Multiple Myeloma | Phase 2 | Completed | Larysa Sanchez | 20 | 2019-10-24 | 2026-10-07 |
| Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients Ixazomib, Lenalidomide - Newly Diagnosed Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 19 | 2019-03-01 | 2023-10-25 |
Showing 20 of 25. Sign in to see all of them.
Multiple Myeloma (12) · Neoplasms, Plasma Cell (2)
Neoplasms (13) · Neoplasms by Histologic Type (13) · Blood Protein Disorders (12) · Cardiovascular Diseases (12) · Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Hemorrhagic Disorders (12) · Hemostatic Disorders (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphoproliferative Disorders (12) · Paraproteinemias (12) · Vascular Diseases (12) · Neoplasms, Plasma Cell (11)
Lenalidomide (17) · Dexamethasone (14) · Bortezomib (11) · daratumumab (10) · isatuximab (5) · Cyclophosphamide (4) · carfilzomib (4) · ixazomib (3) · Melphalan (2) · Prednisone (2) · fludarabine (2) · iberdomide (2) · Aspirin (1) · Blood Specimen Collection (1) · Calcium Dobesilate (1)
The First Affiliated Hospital of Soochow University (4) · PETHEMA Foundation (2) · Abramson Cancer Center at Penn Medicine (1) · Al-Rasheed University College (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · AstraZeneca (1) · Celgene Corporation (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Dana-Farber Cancer Institute (1) · Fuling Zhou (1) · GlaxoSmithKline (1) · Jinling Hospital, China (1) · Kite, A Gilead Company (1) · Larysa Sanchez (1) · Massachusetts General Hospital (1)
United States (8) · China (6) · France (5) · Germany (5) · Spain (5) · Australia (3) · Austria (3) · Greece (3) · Italy (3) · Poland (3) · United Kingdom (3) · Belgium (2) · Brazil (2) · Canada (2) · Czechia (2)
Adil S Al-Oqaby, PhD (1) · Alaaldin S Naji, PhD (1) · Ali M Jawad, PhD (1) · Ammer F Majid, PhD (1) · Andrew Yee, MD (1) · Antonio Palumbo, M.D. (1) · Bassam F Matti, PhD (1) · Cliford Mo, MD (1) · Cyrus Khandanpour, Prof. Dr. (1) · Dan Vogl (1) · Emilie Chalayer, MD (1) · Enrique M Ocio, Dr (1) · Fuling Zhou (1) · Hawraa D Jumaa, PhD (1) · Hayder A Fawzi, PhD (1)
PMID 22571200, PMID 23242595, PMID 25840600, PMID 33461512, PMID 35172566, PMID 40769684
2017 (1)